Synapse - Daniel Fontes Santos De Teive Argolo

Daniel Fontes Santos De Teive Argolo

Research Focus

Former Employee. SKI Medicine; Research Fellow

Recent additions – View all

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
Meeting Abstract

Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S.; more...
Cancer Research (2017)

Fulltext@MSK | Save
Activity of HP-based therapies as third and later lines for the treatment of HER2-positive metastatic breast cancer: A retrospective study from a single institution
Meeting Abstract

Argolo, D.; Friedman, M.; Smyth, L.; Iyengar, N.; Singh, J.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C.; Dang, C.
Cancer Research (2016)

Fulltext@MSK | Save
Phase II study of gemcitabine, trastuzumab, and pertuzumab in the treatment of metastatic HER2-positive breast cancer after prior trastuzumab/pertuzumab- or pertuzumab-based therapy
Meeting Abstract

Iyengar, N. M.; Argolo, D.; Smyth, L.; Chen, M. F.; Hudis, C. A.; Dang, C. T.
Cancer Research (2016)

Fulltext@MSK | Save

Co-authors at MSK

Types of Work

Publications